Inzolfi

Fingolimod, the active ingredient in Inzolfi, is a sphingosine‑1‑phosphate receptor modulator presented as an oral tablet for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients. GNH USA supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inzolfi (fingolimod) is used in the management of relapsing forms of multiple sclerosis, a disease mediated by immune‑driven inflammation.

Relapsing‑Remitting MS: reduces the frequency of clinical relapses and slows disability progression. Active Secondary Progressive MS: decreases relapse rate and disease activity. Clinically Isolated Syndrome with high risk of conversion: delays conversion to definite multiple sclerosis.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Nasopharyngitis: upper respiratory symptoms such as sore throat or runny nose. - Diarrhoea: loose stools that may resolve with continued therapy. - Elevated liver enzymes: mild increases in ALT/AST detected on routine labs. - Hypertension: new‑onset or worsening blood pressure. - Fatigue: generalised tiredness without specific cause.

Serious or Rare Side Effects: - Severe infections: opportunistic infections requiring medical attention. - Cardiac arrhythmia: bradycardia or atrioventricular block, especially after first dose. - Macular edema: visual disturbances due to retinal swelling. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating brain infection. - Severe liver injury: marked transaminase elevation or hepatitis. - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis.

Before initiating therapy, clinicians should assess cardiac, hepatic and infection risk.

Cardiac monitoring: obtain baseline ECG and observe patients for at least six hours after the first dose due to potential bradycardia. Infection risk: avoid starting treatment in patients with active infections and monitor for signs of new infections. Liver function: perform baseline and periodic liver enzyme tests. Vaccination: administer required live vaccines before therapy; avoid live vaccines during treatment. Pregnancy and breastfeeding: contraindicated unless benefits outweigh risks; discuss with a specialist. Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Fingolimod may interact with several medicines that affect immune function or cardiac conduction.

Major Interactions (Avoid): - Live attenuated vaccines: increased risk of vaccine‑derived infection. - Concomitant immunosuppressants: heightened susceptibility to serious infections. - QT‑prolonging drugs: additive risk of cardiac arrhythmias.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask fingolimod‑induced bradycardia. - CYP4F2 inhibitors: can raise fingolimod plasma concentrations. - Antihypertensives: monitor blood pressure for additive hypotensive effect.